HF
CCCC icon

HRT Financial’s C4 Therapeutics CCCC Stock Holding History

HRT Financial’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-162,930
Closed -$557K – 4295
2026
Q1 		$428K Buy
+162,930
New +$384K ﹤0.01% 2644
2025
Q3 		– Sell
-71,106
Closed -$101K – 2913
2025
Q2 		$101K Buy
71,106
+58,072
+446% +$84.5K ﹤0.01% 2209
2025
Q1 		$20K Buy
+13,034
New +$38.9K ﹤0.01% 2302
2023
Q2 		– Sell
-119,612
Closed -$375K – 2537
2023
Q1 		$375K Buy
+119,612
New +$704K ﹤0.01% 1576
2022
Q4 		– Sell
-57,088
Closed -$500K – 2519
2022
Q3 		$500K Sell
57,088
-38,653
-40% -$401K 0.01% 1536
2022
Q2 		$721K Buy
+95,741
New +$842K 0.01% 1230

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HRT Financial's CCCC Position: Q2 2026 in Review

HRT Financial sold out of C4 Therapeutics (CCCC) in Q2 2026, closing a stake of 162,930 shares — an estimated $557K sold.

HRT Financial first reported a position in CCCC in Q2 2022 and held it in 6 quarters. The position peaked at $721K in Q2 2022. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • HRT Financial reported no remaining C4 Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 162,930 C4 Therapeutics shares in Q2 2026, an estimated $557K.
  • HRT Financial first reported a position in C4 Therapeutics in Q2 2022 and held it in 6 quarters.
  • HRT Financial's C4 Therapeutics position peaked at $721K in Q2 2022.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.